Microbix Biosystems Income Statement

Financials in millions CAD. Fiscal year is October - September.

Millions CAD. Fiscal year is Oct - Sep.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Sep '25 Sep 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021
Revenue	14.81	18.59	25.39	16.51	19.08	18.59
Revenue Growth (YoY)	-34.81%	-26.81%	53.77%	-13.43%	2.60%	76.66%
Cost of Revenue	8.52	8.73	10	9.03	7.95	7.55
Gross Profit	6.29	9.85	15.39	7.48	11.12	11.04
Selling, General & Admin	11.16	9.1	9.37	8.17	6.72	5.17
Research & Development	2.38	2.33	2.13	2.05	1.8	1.03
Other Operating Expenses	0.13	0.13	-0.01	3.08	-	-
Total Operating Expenses	13.67	11.56	11.49	13.3	8.51	6.21
Operating Income	-7.38	-1.71	3.91	-5.82	2.61	4.84
Total Non-Operating Income (Expense)	0.7	0.6	0.23	0.38	0.74	1.09
Pretax Income	-6.68	-1.11	4.14	-5.43	3.35	5.92
Provision for Income Taxes	-0.06	-0.06	0.15	-	0.08	-
Net Income	-5.72	-2.25	3.52	-0.04	1.79	3.23
Net Income to Common	-5.72	-2.25	3.52	-0.04	1.79	3.23
Net Income Growth	-	-	-	-	-44.68%	-
Shares Outstanding (Basic)	139	139	138	138	135	115
Shares Outstanding (Diluted)	138	139	138	138	142	142
Shares Change (YoY)	0.03%	0.48%	0.42%	-2.67%	0.00%	26.40%
EPS (Basic)	-0.04	-0.02	0.03	-	0.01	0.03
EPS (Diluted)	-0.04	-0.02	0.03	-	0.01	0.03
EPS Growth	-	-	-	-	-50.00%	-
Free Cash Flow	-5.49	-0.88	2.71	-2.11	1.44	0.86
Free Cash Flow Growth	-	-	-	-	66.64%	-
Free Cash Flow Per Share	-0.04	-0.01	0.02	-0.02	0.01	0.01
Gross Margin	42.49%	53.02%	60.61%	45.30%	58.32%	59.40%
Operating Margin	-49.79%	-9.18%	15.38%	-35.21%	13.68%	26.01%
Profit Margin	-38.62%	-12.08%	13.86%	-0.24%	9.38%	17.39%
FCF Margin	-37.07%	-4.72%	10.68%	-12.78%	7.55%	4.65%
EBITDA	-5.54	0.07	5.52	-4.66	3.65	5.66
EBITDA Margin	-37.39%	0.40%	21.73%	-28.20%	19.12%	30.43%
EBIT	-7.38	-1.71	3.91	-5.82	2.61	4.84
EBIT Margin	-49.79%	-9.18%	15.38%	-35.21%	13.68%	26.01%
Effective Tax Rate	0.83%	5.02%	3.64%	0.00%	2.30%	0.00%